EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, LXEO: Lexeo Therapeutics Inc

11 Nov 25 12:44
LAST:

8.820

CHANGE:
 0.30		OPEN:
8.510		HIGH:
8.907		ASK:
0.000		VOLUME:
258.5K
CHG(%):
3.52		PREV:
8.520		LOW:
8.250		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 258.5108.9078.2508.820258.5K
10 Nov 258.2908.5958.0588.5201.43M
07 Nov 258.3008.3557.6608.1902.85M
06 Nov 258.2308.6178.2008.4201.48M
05 Nov 258.2708.5208.0908.2002.25M
04 Nov 258.7009.0408.1408.3502.99M
03 Nov 259.3909.4008.7859.0402.24M
31 Oct 259.41010.0909.30010.0101.04M
30 Oct 259.84010.0009.3759.4301.28M
29 Oct 259.97010.3809.6709.9101.21M

COMPANY PROFILE

Name:Lexeo Therapeutics Inc
About:Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:345 Park Avenue South, New York, NY, United States, 10010
Website:https://www.lexeotx.com
CIK:0001907108
ISIN:US52886X1072
FIGI:BBG00YB1C8M5

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-2.93 
Forward P/E:-3.61 
PEG Ratio:0.47 
Price to Book:3.91 
Return on Assets:-0.42 
Return on Equity:-0.75 
EPS Ratio:-3.21 
Shares:54.0M 
Market Cap:476.29M 

TECHNICAL INDICATORS

MA5:8.444.5%
MA10:8.900.9%
MA20:9.123.4%
MA50:7.3919.3%
MA100:5.9248.9%
MA200:4.6988.2%
STO9:36.58
STO14:31.74
RSI14:46.86
WPR14:-63.23
MTM14:-0.12
ROC14:-0.01 
ATR:0.71 
Week High:9.042.5%
Week Low:7.6615.1%
Month High:10.3817.7%
Month Low:7.6688.2%
Year High:11.7232.9%
Year Low:1.45508.3%